Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Cervical Cancer
When would you offer extra-fascial hysterectomy to patients with low-risk early-stage cervical cancer in light of data from the ConCerv trial?
ConCerv trial: Schmeler et al., PMID 34493587
Answer from: at Academic Institution
Stage 1A1 and 2
Sign in or Register to read more
17401
Related Questions
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
If a patient meets criteria for extrafascial hysterectomy for early-stage cervical cancer, how do you determine your surgical approach (abdominal vs laparoscopic)?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy?
How would you manage a female in her 40s with stage III cervical cancer with hydronephrosis and Crohn's disease?
Do the results of the ConCerv and SHAPE trials alter how you might counsel a patient incidentally found to have ≤IB1 after simple hysterectomy?
Would you offer post operative radiation for a patient who had findings of lymphovascular invasion on salvage resection of a recurrent obturator node after definitive chemoradiation for cervical cancer?
How would you manage bulky cervical adenocarcinoma that incompletely responded to primary chemoradiation?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?